Top Markets
Coin of the day
Angion Biomedica Corp. Angion Biomedica Corp.

Angion Biomedica Corp.

ANGN
Rang in Aktien #27858
Angion Biomedica Corp. operates as a biopharmaceutical enterprise,... Angion Biomedica Corp. operates as a biopharmaceutical enterprise, concentrating its efforts on the identification, advancement, and market introduction of small molecule treatments for severe organ damage and scarring conditions. Its primary investigational compound, ANG-3070, is an orally administered tyrosine kinase receptor inhibitor currently being developed to address fibrotic ailments, particularly those impacting the kidneys and lungs. The company's product pipeline also features ANG-3777, a hepatocyte growth factor mimetic engineered to treat acute organ injuries like delayed graft function, in addition to initiatives for ROCK2 inhibitors targeting fibrotic diseases and a CYP11B2 inhibitor program. Established in 1998, Angion Biomedica Corp. maintains its headquarters in Uniondale, New York.
Aktienkurs
$1.00
Zuletzt synchronisiert: 2023-06-01
Marktkapitalisierung
$30.11M
Veränderung (1 Tag)
2.04%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Angion Biomedica Corp. (ANGN)

Kategorie

Kursverlauf für Angion Biomedica Corp. (ANGN)
Höchster Schlusskurs: $1.00 am 2023-06-01

Niedrigster Schlusskurs: $20.49 am 2021-02-01
Kursverlauf der Aktie von Angion Biomedica Corp. von 2021 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2023 18.73%
2022 -70.78%
2021 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$552.07 39.99%
US
$168.77 527.63%
US
$1.03K 56.22%
NL
$121.65 -14.34%
AU
$753.28 5.84%
CH